Molecular targeted therapies in endometrial cancer: Current concepts and future challenges

The treatment of advanced and recurrent endometrial cancer is hampered by a paucity of effective agents and minimal durable response. Numerous potentially druggable molecular aberrations and the need for novel therapies have led to significant interest in the use of targeted agents in this disease. Although early results have been promising, targeted therapy has yet to reach its considerable potential in endometrial cancer. Challenges include paucity of tissue for testing, especially in metastasis, lack of predictive biomarkers, and appropriate trial design. Our growing understanding of the molecular context of endometrial tumors will continue to inform the development of rational clinical trials to incorporate targeted therapy into the standard treatment of endometrial cancer.